Structured Administration and Supply Arrangement (SASA) – Issued for a Health Organisation

TITLE:	Intramuscular Benzathine Benzylpenicillin G (BPG) for Administration for the Rheumatic Heart Disease Program

1. **Authority:**

   Issued by the Chief Executive Officer (CEO) of the WA Country Health Service (WACHS) under Part 6 of the Medicines and Poisons Regulations 2016.

2. **Scope and Criteria:**

   This SASA authorises the health professionals and actions specified in the table below.

Practitioners:	Nurses, Midwives and Aboriginal Health Practitioners working within their scope of practice as defined by the WACHS Administration of Intramuscular Benzathine Benzylpenicillin G for Acute Rheumatic Fever and Rheumatic Heart Disease Policy.
Practice setting and/or service:	When employed by or contracted to provide services for WACHS to manage the public health program for acute rheumatic fever and rheumatic heart disease for patients on the Western Australia Rheumatic Heart Disease Register.
Approved activity:	Administration
Approved medicine:	• Medicine name: Benzathine benzylpenicillin G • Route: Intramuscular injection • Dose: < 20 kgs - 600,000 units ≥ 20 kgs - 1,200,000 units • Frequency: Every 21-28 days • Schedule: 4
Approved indication(s) (acute) or public health program:	Management of acute rheumatic fever and rheumatic heart disease via the Rheumatic Heart Disease Program.
WACHS endorsed policy document(s) e.g. clinical practice guidelines, procedure, policy	Must be used in accordance with the following WACHS endorsed policy document(s): WACHS Medication Prescribing and Administration Policy WACHS Administration of Intramuscular Benzathine Benzylpenicillin G for Acute Rheumatic Fever and Rheumatic Heart Disease Policy

3. **General Conditions:**

The approved activity (administration and/or supply) of the identified medicine under this SASA is subject to the following conditions:

a. The Nurse, Enrolled Nurses (medication administration competent), Midwives and Aboriginal Health Practitioners must only administer and/or supply the medicine per the above criteria within their clinical scope of practice.
b. Medicine selection, administration and/or supply and monitoring must be in accordance with WACHS endorsed clinical practice guidelines, procedure or procedure identified in section 2 above.
c. If related to vaccinations, written or documented verbal consent must be obtained from the person, parent or guardian, before each instance of immunisation.
d. If related to Schedule 8 medicines, administration and/or supply must be in accordance with Part 11 of the Medicines and Poisons Regulations 2016.
e. Administration and/or supply must be recorded in the patient's health care record and include the minimum requirements outlined in regulation 143 of the Medicines and Poisons Regulations 2016. Record keeping for administration and/or supply is in accordance with Part 12 of the Medicines and Poisons Regulations 2016. S4 administration documentation must be kept for 2 years and S8 administration documentation must be kept for 5 years.
f. The medicines are procured by an authorised person or an appropriate Medicines and Poisons Permit holder. Procurement, storage, administration and supply is in accordance with Part 9 of the Medicines and Poisons Regulations 2016.

4. **Issued by:**

Name:	Jeff Moffet
Signature:	
Position:	WACHS Chief Executive
Date:	16/08/2025
Expiry:	21/07/2027
Issue number:	V2.0 - ED-CO-25-339596

Enquiries to: Rheumatic Heart Disease Program, Population Health
Email: RHD.Register2@health.wa.gov.au

5. **References:**

a. Medicines and Poisons Regulations 2016
b. RHDAustralia (ARF/RHD writing group). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (3rd edition); 2020. Available from www.rhdaustralia.org.au

Approval for Issuing (can be removed for publication to internet, original to be kept on record)			
WACHS Medicines and Therapeutics Committee			
Minute number:	August 2025	Date endorsed:	Out-of-session – 22/07/2025
WACHS Senior Medical Practitioner			
Name and position:	DR HELEN VAN GESSEL, EXECUTIVE DIRECTOR CLINICAL EXCELLENCE		
Date approved:	23/07/2025	Signature: